Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed .
Product Name | Dacomitinib |
Synonyms | PF-299804 (Dacomitinib,PF-00299804);PF299804, PF299);Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804) |
CAS | 1110813-31-4 |
MF | C24H25ClFN5O2 |
MW | 469.9390032 |
EINECS | N/A |
Product Categories | -;Anti-cancer&immunity;Inhibitors |
Mol File | 1110813-31-4.mol |
![]() |
SHIJIAZHUANG DINGMIN PHARMACEUTICAL SCIENCES CO., LTD.
All Rights Reserved.(Terms of Use) Developed and Managed by Infocom Network Private Limited. |